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Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also known as “Nasu-
Hakola disease,” is a globally distributed recessively inherited disease leading to death during the 5th decade of
life and is characterized by early-onset progressive dementia and bone cysts. Elsewhere, we have identified PLOSL
mutations in TYROBP (DAP12), which codes for a membrane receptor component in natural-killer and myeloid
cells, and also have identified genetic heterogeneity in PLOSL, with some patients carrying no mutations inTYROBP.
Here we complete the molecular pathology of PLOSL by identifying TREM2 as the second PLOSL gene. TREM2
forms a receptor signaling complex with TYROBP and triggers activation of the immune responses in macrophages
and dendritic cells. Patients with PLOSL have no defects in cell-mediated immunity, suggesting a remarkable capacity
of the human immune system to compensate for the inactive TYROBP-mediated activation pathway. Our data
imply that the TYROBP-mediated signaling pathway plays a significant role in human brain and bone tissue and
provide an interesting example of how mutations in two different subunits of a multisubunit receptor complex
result in an identical human disease phenotype.
SinceTYROBP encodes a cell-surface receptor element that
interacts with many different proteins depending on the
cell type, we used a genetic approach to search for genes
involved in polycystic lipomembranousosteodysplasiawith
sclerosing leukoencephalopathy (PLOSL [MIM 221770]),
also known as “Nasu-Hakola disease” (Nasu et al. 1973;
Paloneva et al. 2001; also see the GeneTests–GeneClinics
Web site). We initially analyzed two informative families
showing exclusion of linkage to the PLOSL locus located
on chromosome 19q13.1 (Pekkarinen et al. 1998a,1998b),
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for segregation of the marker haplotypes flanking genes
that encode the polypeptides interacting with TYROBP.
These genes included those for TYROBP-associated re-
ceptors SIRPBETA1 (chromosome 20p13) (Dietrich et al.
2000), TREM1 (chromosome 6p21.2), TREM2 (chro-
mosome 6p21.2) (Bouchon et al. 2000), LY95 (NKp44,
chromosome 6p22.1) (Vitale et al. 1998), MDL1 (chro-
mosome 7q33) (Bakker et al. 1999), CD94 (chromosome
12p13.3) (Lanier et al. 1998b), KIR2DS2 (chromosome
19q13.4) (Lanier et al. 1998a), and NKG2C (chromosome
12p13.1) (Lanier et al. 1998b). Furthermore, haplotypes
of chromosomal regions containing genes for the intracel-
lular protein tyrosine kinases (PTKs) SYK (chromosome
9q22.1) and ZAP70 (chromosome 2q11.2) (Lanier et al.
1998a; McVicar et al. 1998) of the downstream signal-
transduction pathway were analyzed for cosegregation.For
haplotype construction, we selected two or three poly-
morphic markers flanking each candidate gene. We ge-
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Figure 1 Pedigrees, haplotypes, and TREM2 mutations in the
Norwegian (A) and Swedish (B) families with PLOSL. Black symbols
denote patients with PLOSL; half-black symbols denote heterozygous
carriers of a mutated TREM2 allele; white symbols denote individuals
who carry two wild-type alleles of TREM2. The 10-cM haplotypes
were constructed by genotyping the following markers in both families:
D6S1616-D6S1575-D6S1549 (from top to bottom in the figure). nt
p position of mutated nucleotide. A, Haplotype 1-8-3 and 558GrA
mutation, showing cosegregation with PLOSL in the Norwegian fam-
ily. Haplotype 4-8-3 in the male carrier probably results from a re-
combination. B, Haplotype 4-7-3 and 233GrA substitution, cosegre-
gating with PLOSL in the Swedish family.
notyped the following polymorphic markers: D6S1616,
D6S1575, andD6S1549, forTREM1,TREM2, andLY95;
D20S198 and D20S906, for SIRBETA1; D7S661 and
D7S2513, forMDL1; D12S336, forCD94; D19S926 and
D19S891, for KIR2DS; D12S77 and D12S1697, for
NKG2C; D9S1836 andD9S1820, for SYK andD2S2222;
and D2S2175, for ZAP70. The position of the genes and
markers were determined by Ensembl, version 3.26.1 (see
the Emsembl Human Web site), and the UCSC Human
Genome Browser (August 6, 2001, draft assembly [see the
UCSC Human Genome Project Working Draft Web site]).
Information on the sequence of the primers is available at
the UCSC Human Genome Browser (see the UCSC Human
Genome Project Working Draft Web site). Genotyping was
performed as described elsewhere (Wessman et al. 2002).
The genotyped families originated from Sweden (Nylander
et al. 1996) and Norway (Edvardsen et al. 1983), and each
had two affected family members (Pekkarinen et al. 1998a;
Paloneva et al. 2000).
The only chromosomal region showing complete coseg-
regation with PLOSL was the 6p21-p22 region covered
by the markers D6S1616, D6S1575, and D6S1549 (fig.
1). This 10-cM DNA region contains genes for TREM1,
TREM2, and LY95. The patients in the Swedish and Nor-
wegian families were homozygous for different haplo-
types, implying two independent mutations. Sequence
analysis of the genomic DNA of the patients revealed
mutations only inTREM2 (for primer sequences, see table
1). The Swedish family had a homozygous G-to-A mu-
tation at position 233 (233GrA), changing tryptophan
78 to a translation termination codon (W78X). This same
mutation also was found in another Swedish family,
which had three affected family members, but DNA for
sequencing was available from only one patient. In the
Norwegian family, a 558GrA mutation was found, re-
sulting in conversion of lysine 186 to asparagine (K186N)
(fig. 2). Neither of these mutations was found in a control
panel of 100 Scandinavian DNA samples.
Since our sequence analyses of TYROBP from one
American (whose family originates from Slovakia [Bird
et al. 1983]), from one Bolivian, and from two Italian
sibs, all of whom have PLOSL, had not revealed muta-
tions, we amplified and sequenced the exons and intron-
exon boundaries of TREM2 from the genomic DNA of
these patients. All had mutations in TREM2: the Amer-
ican patient was homozygous for a 401ArG substitu-
tion, resulting in conversion of the aspartic acid resi-
due to glycine, at position 134 (D134G). The two Italian
patients were homozygous for a conversion of nucleotide
T to nucleotide C, in the splice-donor consensus site at
the second position of intron 3 (4822TrC), whereas
their two unaffected sibs were homozygous for the normal
allele. In the Bolivian patient, a homozygous 132GrA
mutation changed tryptophan at position 44 to a trans-
lation stop codon (W44X). None of the mutations was
observed in a control panel of 100 white individuals. The
positions of the identified TREM2 mutations are shown
in figure 2.
The 230-amino-acid TREM2 polypeptide belongs to
the immunoglobulin superfamily (Ig-SF) and is predicted
to consist of a 13-amino-acid signal peptide followed by
a 154-amino-acid extracellular domain encoded by ex-
ons 2 and 3, with two cysteines potentially involved in
generating an intrachain disulfide bridge of the Ig-SF
V–type fold. The 33-amino-acid transmembrane domain
is followed by a short, 30-amino-acid long cytoplasmic
domain (Bouchon et al. 2000). On the cell membrane
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Figure 2 Schematic presentation of the identified PLOSL mu-
tations in TREM2. The positions of other loci for TYROBP-associated
cell-surface receptors,TREM1 andLY95, as well as of the polymorphic
“D” markers used in the segregation analysis, are indicated.
Table 1
Genomic and cDNA Primer Sequences Used to Amplify TYROBP, TREM1, TREM2, and ACTB
FRAGMENT
PRIMERa
(5′r3′)
Forward Reverse
TYROBP:
Exon 1 tggggacggaggtgaagttt cccatcccaacacccacttt
Exon 2 gcctgtgggtttctcccaga ggcagggaggtttggaaagg
Exon 3 ccgtctctcccacacccttt cctccattaccatccctttgga
Exon 4 gggctgggtaaactcccaga cccagcccctcttcacacat
Exon 5 gcagaggagaagggggaaca agtattggggagcggtctgg
Intron 1 gtggtgagttaggggcttcc tctgcacaacttgtcctgtgg
TYROBP by quantitative RT-PCR atggggggacttgaaccc tcatttgtaatacggcctctgtg
TREM1:
Exon 1 acttaactgagaagtgagtcttggtctc gcagtagtatatttgctgtcccatagtag
Exon 2 atatgggtggttggacaagaaa agacagactgctgggaatcct
Exon 3 ctcatccacattttcatccatacatc gacatttctacccagactaatgtgact
Exon 4 gcaaggatctaagcagaggaga tgtttggggctgtaacttcttt
TREM2:
Exon 1 caccgccttcataattcacc gactcctcctcccctctgtc
Exon 2 agtgggtggttctgcacac tccttcagggcaggattttt
Exon 3 gctctagttgccttgtaatttgtagtt agtgtaatgacctgatccacataggac
Exons 4 and 5 agcaaaatctcttgtctttttctcatc cctagaactcaagtctcttgactatgg
Exon 4 seq tcttccttcacgtgtctctcag cccattccctgagagaagatt
Exon 5 seq cctcaaggagcaaaatctcttgt ccagggtatcagctccaaac
TREM2 probe atggagcctctccggctgct tcacgtgtctctcagccctg
TREM2 by quantitative RT-PCR atggagcctctccggctgct tcacgtgtctctcagccctg
ACTB:
ACTB by quantitative RT-PCR tcacccacactgtgcccatctacga cagcggaaccgctcattgccaatgg
a Except in the cases of exons 4 and 5 ofTREM2 that were sequenced by primers with the designation
ending with “seq,” PCR primers were used for sequencing.
of macrophages and dendritic cells, TREM2 is bound
noncovalently to a disulfide-bonded TYROBP homo-
dimer (Campbell and Colonna 1999; Bouchon et al.
2001b). This interaction is mediated by oppositely
charged amino acids in the transmembrane domains of
these proteins; one of these amino acids is a positively
charged lysine in TREM2, and the other is a negatively
charged aspartic acid in TYROBP. The interaction be-
tween TREM2 and an unidentified ligand results in the
phosphorylation of tyrosines in the intracellular tyro-
sine-based activation motif (ITAM) of TYROBP. Phos-
phorylated ITAM binds the cytosolic PTKs SYK and
ZAP70, and this interaction leads to an increase in in-
tracellular Ca2 concentration and to subsequent cellular
activation (Lanier and Bakker 2000).
The mutations in the Bolivian (W44X) and Swedish
(W78X) patients are predicted to result in the generation
of a truncated protein lacking the transmembrane and
cytoplasmic domains. In the Italian patients, the ho-
mozygous mutation of the splice donor site probably
results in the skipping of exon 3 from the mature mRNA,
also leading to a truncated protein. The mutation in the
Norwegian family with PLOSL changes the positively
charged lysine to asparagine in the transmembrane do-
main of TREM2. This has been shown to disrupt the
association with (McVicar et al. 1998; Bakker et al.
1999), as well as the cell-surface expression of, TYROBP
(Lanier et al. 1998b; Smith et al. 1998). Thus, all these
PLOSL mutations are likely to result in complete loss of
function of TREM2. The clinical phenotype of these
patients with PLOSL was identical with that of those
carrying mutations in TYROBP (table 2).
To gain some insight into the peculiar tissue manifes-
tations of PLOSL in the brain and bone, we compared
the levels of the TREM2 steady-state transcripts with
those of TYROBP in human tissues and cell lines rele-
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Table 2
Comparison of PLOSL Manifestations in Patients with Mutations in Either TREM2 or TYROBP
SYMPTOM(S)
TREM2a
TYROBPbI:1 I:2 II:1 III:1 IV:1 IV:2 V:1
Bones (3rd decade):
Skeletal pain        
Bone cysts or fractures        
CNS (4th–5th decades):
Frontal-lobe syndromec        
Progressive dementia        
Other disturbances of higher cortical functionsd     NA   
Convulsions    e  NA  
Primitive reflexes     NA NA  
Diffuse slowing in the electroencephalogram      NA  
Brain atrophyf        
a Roman numerals denote the nationality of the family: Ip Italian; IIp U.S.; IIIp Bolivian; IVp Norwegian;
Vp Swedish. The arabic numerals denote the individual tested.p present;p absent; NAp data not available.
b Data are based on reports by Hakola (1972, 1990), Hakola and Partanen (1983), Hakola and Puranen (1993),
and Paloneva et al. (2000, 2001).
c Euphoria and loss of social inhibitions.
d Agnostic-aphasic-apraxic symptoms.
e Convulsions appeared after neurosurgery.
f Confirmed by autopsy, computed tomography, or, magnetic-resonance imaging.
vant to the clinical phenotype, using northern-blot anal-
yses. In the CNS, the signal-intensity levels of TREM2
transcripts closely followed those of TYROBP, being
strongest in the basal ganglia (putamen, caudate nucleus,
and substantia nigra), corpus callosum, medulla oblon-
gata, and spinal cord. This would suggest regional coex-
pression of these two genes encoding interactive proteins
in the CNS. In contrast to the strong steady-state mRNA
signal intensities of TYROBP in hematological cells and
tissues, we detected TREM2 signals only in lymph nodes
(fig. 3).
The characteristic bone cysts in the patients with
PLOSL may reflect chronic dysfunction of osteoclasts.
To characterize the expression of TREM2 and TYROBP
in bone, we performed quantitative RT-PCR analysis of
mRNA in cells differentiating along the osteoclastic line-
age. We stimulated monocytes by use of either pseu-
dosynovial fluid obtained from total-hip arthroplasties
or a combination of cytokines (comprising macrophage
colony–stimulating factor [R&D Systems], receptor ac-
tivator of NF-kB ligand [Alexis Biochemicals], and in-
terleukin-1b [R&D Systems]). With these inductors,
multinuclear tartrate-resistant acid phosphatase– and
cathepsin K–positive osteoclastic cells can be generated
from peripheral blood monocytes (Kim et al. 2001). The
relative amount of TYROBP transcripts was ∼200 times
higher than that of TREM2, but stimulation increased
the expression of both TYROBP and TREM2 (fig. 4).
This would suggest that osteoclasts, potentially involved
in the pathogenesis of PLOSL, express both TREM2 and
TYROBP.
TREM2 polypeptide has a structure similar to that of
TYROBP-associated TREM1 and LY95, these proteins
constituting a superfamily of activating cell-surface re-
ceptors (Daws et al. 2001). TREM1 is strongly up-reg-
ulated in cells that mediate acute inflammatory responses
to bacterial infection (i.e., neutrophils and monocytes)
(Bouchon et al. 2001a), whereas TREM2 is expressed
on macrophages and monocyte-derived dendritic cells,
suggesting that TREM2 plays a role in chronic, rather
than in acute, inflammation (Bouchon et al. 2000). This
observation would agree well with the late onset and
slow progression of PLOSL, which potentially results
from chronic inflammation in the CNS and bone.
We have identified mutations in all 39 patients with
PLOSL who were available to us; 31 (79%) were found
to carry a mutation in TYROBP, and 8 (21%) were
found to carry a mutation in TREM2. All of our 25
Finnish patients have the same founder mutation in TY-
ROBP, a 5.3-kb deletion encompassing exons 1–4, des-
ignated “PLOSLFin” (Paloneva et al. 2000). Other pa-
tients carrying TYROBP mutations are from Sweden
(PLOSLFin, one family) (Paloneva et al. 2000), Norway
(PLOSLFin, one family) (Paloneva et al. 2000; Tranebjærg
et al. 2000), Japan (PLOSLJpn, 141delG, one family) (Pa-
loneva et al. 2000), and Brazil (a large deletion encom-
passing exons 1–4, one family) (J.P., unpublished data).
Families with mutations in TREM2 originate from the
United States, Norway, Sweden, Italy, and Bolivia. The
molecular pathogenesis of PLOSL seems to be explained
by these two genes.
We are aware of one earlier example of a human disease
resulting from defects in different components of the same
signaling pathway. Autosomally dominant holoprosen-
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Figure 3 Northern-blot analysis of human tissues, with radio-
labeled human TREM2 and TYROBP cDNAs used as probes. We
hybridized human multiple-tissue northern blots (Clontech), with each
lane containing 2 mg of poly(A) RNA, and a multiple-tissue mRNA
expression array (Clontech) (J.P., unpublished data), using a [32P]-la-
beled TREM2 cDNA probe, according to the manufacturer’s instruc-
tions. We generated the probe, corresponding to the transcribed region
of TREM2, by PCR, from a cDNA clone (GenBank accession number
BF343916) obtained from the IMAGE Consortium. We labeled and
purified the probe by using the Rediprime II Random Prime Labelling
System (Amersham Pharmacia Biotech) and the QIAquick Nucleotide
Removal Kit (Qiagen) and performed the hybridizations by using
ExpressHyb hybridization solution, according to the manufacturer’s
(Clontech) protocol. A strong steady-state TYROBP mRNA signal is
observed in hematological cells and tissues such as peripheral blood
leukocytes (PBL) and spleen, whereas TREM2 can be detected only
in lymph nodes. The intensities of the steady-state mRNA signals of
TREM2 and TYROBP in different parts of the CNS are similar. In
the CNS, relatively strong northern-blot signals can be detected in the
basal ganglia (putamen and caudate nucleus), medulla, spinal cord,
and corpus callosum. TYROBP northern-blot data have been pub-
lished elsewhere (Paloneva et al. 2000).
Figure 4 Quantitative RT-PCR analysis of the expression of
TREM2 (A) and TYROBP (B). Monocytes were stimulated with either
a cytokine combination (comprising M-CSF, RANKL, and IL-1b) (cc)
or pseudosynovial (PS) fluid, for 24 h, along the osteoclastic lineage.
Human monocytes from healthy individuals were isolated from buf-
fy-coat cells over Ficoll-Paque (Amersham Pharmacia Biotech). Mono-
nuclear cells were collected, washed with PBS, and resuspended in
serum-free macrophage medium (GIBCO) with antibiotics. Approxi-
mately cells/well were allowed to adhere to six-well610–15# 10
plates, for 1 h at 37C. Nonadherent cells were washed away with
PBS, and mononuclear cells were stimulated, for 24 h, with either
cytokines (i.e., M-CSF, RANKL, and IL-1b) or PS fluid. Stimulations
were performed four times, in duplicate. Total RNA was isolated by
use of TRIzol reagent, according to the manufacturer’s instructions
(GibcoBRL/Life Technologies). The RNA concentration was measured
spectrophotometrically, and the quality was ascertained by ethidium
bromide agarose gel. Three micrograms of the RNA was treated with
DNase, and 2 mg of RNA was transcribed to cDNA (SuperScript
Preamplification System; GibcoBRL). The number of copies of TY-
ROBP and TREM2 in stimulated cells was determined by quantitative
RT-PCR amplification from 200 ng of cDNA in LightCycler SYBR
Green I PCR mix, by a LightCycler PCR machine (Roche/Molecular
Biochemicals). The identity of the product was verified by melting-
curve analysis. Serial dilutions of human TREM2 cDNA (GenBank
accession number BF343916) and of TYROBP cDNA (GenBank ac-
cession number AA481924), cloned in a plasmid vector, were used to
determine the copy number of the amplicon per 1,000 copies ofACTB
(b-actin) cDNA (GenBank accession number X00351). Each individual
sample was amplified at least twice for both genes. Statistical analyses
were performed by one-way ANOVA with Bonferroni’s multiple-com-
parison test (GraphPad Prism, version 3.00 for Windows; GraphPad
Software). The values are expressed as the mean  SEM of copies
per 1,000 ACTB mRNA. Neg p negative controls. A, Expression of
TREM2, which is increased in both the cc-stimulated (234  195
copies of mRNA) and PS fluid–stimulated (174 55 copies of mRNA)
monocytes, compared with that in the negative controls (96  58
copies of mRNA). However, the difference remained statistically non-
significant ( ). B, Expression ofTYROBP,which also is increasedP 1 .05
in cc-stimulated (27,190  10,270 copies of mRNA; ) and PSP 1 .05
fluid–stimulated (54,740 18,220 copies of mRNA; , denotedP ! .05
by an asterisk [*]) cells, compared with that in the negative controls
(14,210  6,290 copies of mRNA).
cephaly results from mutations in genes encoding the sig-
naling molecule, SHH, and its receptor, PTCH, in the
sonic hedgehog signaling pathway (Ming et al. 2002).
Interestingly, patients with PLOSL who are homozy-
gous for mutations in either TREM2 orTYROBP display
identical CNS and bone manifestations (table 2)—and no
immunological symptoms (Paloneva et al. 2000). This
indicates a remarkable capacity of the human immune
system to compensate for the loss of TYROBP-mediated
activating signals. Our findings suggest either significant
functional redundancy or the presence of additional cell-
surface molecules capable of replacing the inactive TY-
ROBP-TREM2 complex in cells of innate immunity.
Although we have now identified the signaling pathway
responsible for PLOSL, the reason for the peculiar tissue
specificity of the symptoms of the patients remains un-
explained. The findings in patients with PLOSL should
motivate further characterization of the cell- and tissue-
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specific function of the TREM2-TYROBP signaling com-
plex in the CNS and bone.
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